CPhI Online

- Research & Development

Vital Signs Solutions receives backing to facilitate mass-scale antibody testing for COVID-19

27 Jul 2020

The company will adapt its digital platform to digitize any COVID-19 antibody rapid test assay and embed this within an app available on smartphones and tablets.

Vital Signs Solutions, an early-stage, startup developing innovative, digital preventative healthcare solutions, has been awarded a significant grant by Innovate UK as part of the UK Government's support for innovation that can alleviate the effects of the COVID-19 crisis.

The company will adapt its digital platform, called PocDoc, to digitize any COVID-19 antibody rapid test assay and embed this within an app available on smartphones and tablets.

The app will be able to collect additional data to help track and analyse the spread of the virus and its impact on the presence of antibodies in the population.

The first version of the app has been finished and will be undergoing real-world beta testing in the coming weeks.

In addition to its efforts to help tackle COVID-19, Vital Signs Solutions is continuing to develop its own range of physical blood tests that are integrated with its PocDoc platform, with results delivered immediately via the PocDoc app.

Steve Roest, CEO of Vital Signs Solutions, commented: A digital platform is critical to facilitate the scaling of antibody testing and we are confident our PocDoc platform can be adapted to solve this problem."